.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Argus Health
Covington
Cerilliant
Farmers Insurance
Merck
AstraZeneca
Deloitte
Fuji

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,794,410

« Back to Dashboard

Which drugs does patent 6,794,410 protect, and when does it expire?


Patent 6,794,410 protects AUBAGIO and is included in one NDA.

This patent has sixteen patent family members in eighteen countries.

Summary for Patent: 6,794,410

Title: Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
Abstract:The invention relates to the use of compound of Formula I in treating patients for the symptoms of multiple sclerosis. ##STR1##
Inventor(s): Wettstein; Joseph (Lebanon, NJ)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:10/113,078
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis UsAUBAGIOteriflunomideTABLET;ORAL202992-001Sep 12, 2012RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
Sanofi Aventis UsAUBAGIOteriflunomideTABLET;ORAL202992-002Sep 12, 2012RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,794,410

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0123571Oct 02, 2001

Non-Orange Book Patents for Patent: 6,794,410

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,569,898 United States Patent: 6569898   ( 1► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,794,410

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1381356► Subscribe
Portugal1381356► Subscribe
Peru05622003► Subscribe
Panama8542901► Subscribe
Luxembourg92366► Subscribe
Honduras2002000110► Subscribe
United Kingdom0123571► Subscribe
Spain2305287► Subscribe
European Patent Office1935416► Subscribe
European Patent Office1381356► SubscribeCA 2014 00005Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
Citi
Cantor Fitzgerald
Fuji
Baxter
Mallinckrodt
Argus Health
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot